Literature DB >> 15382215

When is a patient too well and when is a patient too sick for a liver transplant?

Robert M Merion1.   

Abstract

1. Liver transplantation is currently offered as a therapeutic option for patients with a wide range of end-stage liver diseases. 2. Conventional wisdom suggests that patients who receive a liver transplant have a greater expected lifetime when compared to comparable candidates on the waiting list. 3. The model for end-stage liver disease (MELD) scoring system is an excellent predictor of mortality on the waiting list and also predicts mortality after liver transplantation. 4. The combination of waiting list mortality risk and posttransplant mortality risk assessed by MELD and other factors can be used to estimate whether candidates are likely to derive a survival benefit from a liver transplant.

Entities:  

Mesh:

Year:  2004        PMID: 15382215     DOI: 10.1002/lt.20265

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  13 in total

1.  MELD as a metric for survival benefit of liver transplantation.

Authors:  Xun Luo; Joseph Leanza; Allan B Massie; Jacqueline M Garonzik-Wang; Christine E Haugen; Sommer E Gentry; Shane E Ottmann; Dorry L Segev
Journal:  Am J Transplant       Date:  2018-02-19       Impact factor: 8.086

2.  Hilar cholangiocarcinoma: expert consensus statement.

Authors:  John C Mansour; Thomas A Aloia; Christopher H Crane; Julie K Heimbach; Masato Nagino; Jean-Nicolas Vauthey
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

3.  Chemical cocktails enable hepatic reprogramming of human urine-derived cells with a single transcription factor.

Authors:  Wei Tang; Ren Guo; Shi-Jun Shen; Yang Zheng; Yu-Ting Lu; Meng-Meng Jiang; Xue Cui; Ci-Zhong Jiang; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2018-10-12       Impact factor: 6.150

4.  Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

Authors:  Arun J Sanyal; Scott L Friedman; Arthur J McCullough; Lara Dimick-Santos
Journal:  Hepatology       Date:  2015-03-19       Impact factor: 17.425

5.  Barriers to the successful treatment of liver disease by hepatocyte transplantation.

Authors:  Kyle A Soltys; Alejandro Soto-Gutiérrez; Masaki Nagaya; Kevin M Baskin; Melvin Deutsch; Ryotaro Ito; Benjamin L Shneider; Robert Squires; Jerry Vockley; Chandan Guha; Jayanta Roy-Chowdhury; Stephen C Strom; Jeffrey L Platt; Ira J Fox
Journal:  J Hepatol       Date:  2010-06-30       Impact factor: 25.083

6.  Outcomes following liver transplantation in intensive care unit patients.

Authors:  Lena Sibulesky; Michael G Heckman; C Burcin Taner; Juan M Canabal; Nancy N Diehl; Dana K Perry; Darren L Willingham; Surakit Pungpapong; Barry G Rosser; David J Kramer; Justin H Nguyen
Journal:  World J Hepatol       Date:  2013-01-27

Review 7.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 8.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

9.  Historical perspective of living donor liver transplantation.

Authors:  See Ching Chan; Sheung Tat Fan
Journal:  World J Gastroenterol       Date:  2008-01-07       Impact factor: 5.742

10.  Moving toward the utilization of all donated liver grafts. The "b-list" concept.

Authors:  D Vrochides; P Metrakos
Journal:  Hippokratia       Date:  2012-10       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.